Literature DB >> 20981680

Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.

Robert Griffiths, Michelle Gleeson, Carolina Reyes, Kevin Knopf, Mark Danese.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20981680     DOI： 10.1002/ajh.21878

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

1.  Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.

Authors:  Robert Griffiths; Joseph Mikhael; Michelle Gleeson; Mark Danese; Martin Dreyling
Journal:  Blood       Date:  2011-08-26       Impact factor: 22.113

2.  Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.

Authors:  Carla Casulo; Jesse G Dixon; Fang-Shu Ou; Eva Hoster; Bruce A Peterson; Howard S Hochster; Pauline Brice; Marco Ladetto; Wolfgang Hiddemann; Robert Marcus; Eva Kimby; Michael Herold; Tina Nielsen; Franck Morschhauser; Mathias Rummel; Anton Hagenbeek; Umberto Vitolo; Gilles A Salles; Qian Shi; Christopher R Flowers
Journal:  Blood Adv       Date:  2021-03-23

3.  Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data.

Authors:  Mark D Danese; Carolina M Reyes; Michelle L Gleeson; Marc Halperin; Sandra L Skettino; Joseph Mikhael
Journal:  Med Care       Date:  2016-04       Impact factor: 2.983

4.  Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.

Authors:  Robert I Griffiths; Michelle L Gleeson; Joseph Mikhael; Mark D Danese
Journal:  J Cancer Epidemiol       Date:  2012-08-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.